Contact
Get in touch.
For partnership, investment, scientific collaboration, or media inquiries.
Evolvia BioPharma, Inc.
Chicago, Illinois
Delaware C-corporation
What we're advancing
A focused, capital-efficient oncology program: isoform-selective PHD1 inhibitors for MSS colorectal cancer, executed through CRO synthesis and academic-core validation, with a parallel non-dilutive NIH SBIR track.